SEC Comment Letter 0000000000-23-001639 to BioLIfe Sciences Inc (CIK 0001929281)
BioLIfe Sciences Inc (CIK 0001929281)
Date: Feb. 17, 2023 · CIK: 0001929281 · Accession: 0000000000-23-001639
AI Filing Summary & Sentiment
File numbers found in text: 024-11898
Letter
United States securities and exchange commission logo February 17, 2023 Justin De Four Chairman, CEO and Director BioLIfe Sciences, Inc. 2831 St. Rose Parkway #200 Henderson, NV 89052 Re:BioLIfe Sciences Inc Post-Qualification Amendment No. 2 to Offering Statement on Form 1-A Filed February 9, 2023 File No. 024-11898 Dear Justin De Four: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Eric Newlan, Esq.
Show Raw Text
United States securities and exchange commission logo
February 17, 2023
Justin De Four
Chairman, CEO and Director
BioLIfe Sciences, Inc.
2831 St. Rose Parkway #200
Henderson, NV 89052
Re:BioLIfe Sciences Inc
Post-Qualification Amendment No. 2 to Offering Statement on Form 1-A
Filed February 9, 2023
File No. 024-11898
Dear Justin De Four:
This is to advise you that we do not intend to review your amendment.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Eric Newlan, Esq.